We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AZ and Nektar’s Movantik Launch Is Delayed as DEA Considers Descheduling Request
AZ and Nektar’s Movantik Launch Is Delayed as DEA Considers Descheduling Request
AstraZeneca and Nektar Therapeutics say they hope to market their newly approved opioid-induced constipation drug Movantik in early 2015, but the launch date remains uncertain as the Drug Enforcement Administration considers a request to deschedule the product.